Clinical Trial Update: Myocet Plus Endoxan for Older Patients With Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Myocet (liposomal doxorubicin) plus Endoxan (cyclophosphamide) in older patients with breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Endoxan (Cyclophosphamide)
• Myocet (liposomal doxorubicin)

Snippet

Sponsor: Hellenic Oncology Research Group | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED